Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester

被引:14
作者
Christiansen, M [1 ]
Norgaard-Pedersen, B [1 ]
机构
[1] Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen, Denmark
关键词
first-trimester screening; free beta-form of human chorionic gonadotrophin; Monte Carlo simulation; pregnancy-associated plasma protein-A;
D O I
10.1111/j.1399-0004.2005.00441.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Inhibin A is a maternal serum marker for fetal Down's syndrome (DS) in the second trimester. We examined whether inhibin A could be used early in the first trimester. Maternal serum concentrations of inhibin A were determined in 81 controls and 27 cases of fetal trisomy 21 in gestational week 5-11. The log MoM (Multiple of the Median of normal pregnancies) inhibin A concentration in DS pregnancies increased with gestational age (p = 0.001) from a mean log MoM (standard deviation) of -0.1754 (0.3712) (n = 11) in week 7-8 to a mean log MoM (standard deviation) of 0.1842 (0.2145) (n = 12) in week 9-11. This corresponded to an increase in inhibin median MoM from 0.67 to 1.53. When inhibin A was used together with pregnancy-associated plasma protein-A, free beta-human chorionic gonadotrophin and nuchal translucency as DS markers, the estimated detection rates were 81.4 and 82.6% in weeks 7-8 and 9-11, respectively, for false-positive rates of 0.9 and 1.0%. The performance of the latter combination early in the first trimester is nearly as good as that of integrated first- and second-trimester screening, with the further advantage that the risk can be reported to the pregnant woman in first trimester.
引用
收藏
页码:35 / 39
页数:5
相关论文
共 39 条
  • [1] Dimeric inhibin a as a marker for Down's syndrome in early pregnancy
    Aitken, DA
    Wallace, EM
    Crossley, JA
    Swanston, IA
    vanPareren, Y
    vanMaarle, M
    Groome, NP
    Macri, JN
    Connor, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (19) : 1231 - 1236
  • [2] Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimesters
    Berry, E
    Aitken, DA
    Crossley, JA
    Macri, JN
    Connor, JM
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (07): : 811 - 817
  • [3] Christiansen M, 1999, PRENATAL DIAG, V19, P905, DOI 10.1002/(SICI)1097-0223(199910)19:10<905::AID-PD658>3.0.CO
  • [4] 2-Q
  • [5] Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers
    Christiansen, M
    Larsen, SO
    Oxvig, C
    Qin, QP
    Wagner, JM
    Overgaard, MT
    Gleich, GJ
    Sottrup-Jensen, L
    Norgaard-Pedersen, B
    [J]. CLINICAL GENETICS, 2004, 65 (01) : 11 - 16
  • [6] Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO
  • [7] 2-6
  • [8] Cuckle HS, 1996, PRENATAL DIAG, V16, P1095
  • [9] Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies
    Dalgliesh, GL
    Aitken, DA
    Lyall, F
    Howatson, AG
    Conner, JM
    [J]. PLACENTA, 2001, 22 (2-3) : 227 - 234
  • [10] IMMUNOASSAYS FOR INHIBIN AND ITS SUBUNITS - FURTHER APPLICATIONS OF THE SYNTHETIC PEPTIDE APPROACH
    GROOME, N
    OBRIEN, M
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 165 (02) : 167 - 176